Outset Medical, Inc.
NASDAQ:OMMedical - Devices
+$0.73 today
- Market cap
- $57.31M
- Beta
- 1.94
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$4.07
Volume 0.05M
Average 0.16M
OM EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Outset Medical, Inc.NASDAQ: OM
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$16.54M, compared with -$15.11M a year earlier. Trailing-twelve-month EBITDA was -$62.35M.
Context
- EBITDA amounted to 52.2% of revenue in FY2025, down 33.9 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$24.39M (+60.9%) for the fiscal year ending Dec 2026, a step up from the +36.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$16.54M-0.4% QoQ
- Last fiscal yearDec 2025
- -$62.37M+36.3% YoY
- LTMMar 2026
- -$62.35M+22.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.4% | +40.0% | +49.4 pp |
| 1 year | +36.3% | +60.9% | +24.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (62.37M) USD
- Year-over-year change
- +36.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (62.37M) | +36.3% |
| FY2024 | 2024-12-31 | (97.89M) | +36.4% |
| FY2023 | 2023-12-31 | (153.79M) | -0.6% |
| FY2022 | 2022-12-31 | (152.81M) | -22.4% |
| FY2021 | 2021-12-31 | (124.86M) | — |
EBITDA vs competitors
How OM compares with its peers on the latest reported figures
- OM's LTM Mar 2026 EBITDA of -$62.35M is the 6th highest of the 10 companies compared; the peer median is -$49M.
- Its year-over-year change of +22.0% is the 5th highest of 10, against a peer median of -11.0%.
- EBITDA amounts to 53.0% of revenue for OM, versus a peer median of 76.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $53.03M | +28.1% | +27.6% | 18.5% | |
| LTM Mar 2026 | $22.67M | +217.1% | +59.4% | 51.1% | |
| LTM Mar 2026 | -$5.23M | +26.2% | — | 1.5% | |
| LTM Mar 2026 | -$41.14M | -191.1% | — | 76.3% | |
| LTM Dec 2025 | -$49M | -11.0% | — | 376.3% | |
| LTM Mar 2026 | -$62.35M | +22.0% | — | 53.0% | |
| LTM Mar 2026 | -$75.47M | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$84.67M | -104.0% | — | 58.4% | |
| LTM Mar 2026 | -$110.64M | -31.7% | — | 17902.8% | |
| LTM Mar 2026 | -$135.55M | -1012.4% | — | 1413.6% | |
| Peer median (excluding OM) | -$49M | -11.0% | +43.5% | 76.3% | |
Competitors are the stored peer set for OM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 102.6M | 115.38M | 130.38M | 113.69M | 119.48M |
| Cost of Revenue | 94.99M | 97.54M | 101.38M | 75.13M | 72.72M |
| Gross Profit | 7.61M | 17.83M | 29M | 38.56M | 46.75M |
| Gross Margin | 7.4% | 15.5% | 22.2% | 33.9% | 39.1% |
| Research & Development | 36.74M | 48.86M | 57.31M | 38.4M | 21.24M |
| Selling, General & Admin | 101.39M | 130M | 141.46M | 113.54M | 92.23M |
| Operating Expenses | 138.13M | 178.85M | 198.77M | 151.94M | 113.46M |
| Depreciation & Amortization | 5.16M | 6.28M | 5.81M | 5.73M | 4.34M |
| EBITDA | (124.86M) | (152.81M) | (153.79M) | (97.89M) | (62.37M) |
| EBITDA Margin | -121.7% | -132.4% | -118.0% | -86.1% | -52.2% |
| Operating Income | (130.52M) | (161.02M) | (169.77M) | (113.38M) | (66.71M) |
| Operating Margin | -127.2% | -139.6% | -130.2% | -99.7% | -55.8% |
| Interest Income | 498K | 3.29M | 10.17M | 9.76M | 7.41M |
| Interest Expense | 1.72M | 3.57M | 12.68M | 23.87M | 13.95M |
| Other Income / Expenses | (1.22M) | (1.64M) | (2.5M) | (14.11M) | (14.22M) |
| Income Before Tax | (131.74M) | (162.66M) | (172.27M) | (127.49M) | (80.94M) |
| Pre-Tax Margin | -128.4% | -141.0% | -132.1% | -112.1% | -67.7% |
| Income Tax Expense | 199K | 295K | 523K | 491K | 718K |
| Net Income | (131.94M) | (162.96M) | (172.8M) | (127.98M) | (81.65M) |
| Net Margin | -128.6% | -141.2% | -132.5% | -112.6% | -68.3% |
| EPS (Basic) | (43.41) | (50.75) | (52.27) | (36.95) | (5.37) |
| EPS (Diluted) | (43.41) | (50.75) | (52.27) | (36.95) | (5.37) |
| Weighted Avg Shares | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M |
| Weighted Avg Shares (Diluted) | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M |
Outset Medical, Inc.
NASDAQ:OM
Intrinsic Alpha fair value
Locked
Current Price
$3.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.